ALCAM/CD166 is overexpressed in colorectal carcinoma and correlates with shortened patient survival. - Wikidata - wikimedia - TriplyDB

ALCAM/CD166 is overexpressed in colorectal carcinoma and correlates with shortened patient survival.

ALCAM/CD166 is overexpressed in colorectal carcinoma and correlates with shortened patient survival.

http://www.wikidata.org/entity/Q41983868

about

The role of immunoglobulin superfamily cell adhesion molecules in cancer metastasis RNA-binding IMPs promote cell adhesion and invadopodia formation.Investigating the correspondence between transcriptomic and proteomic expression profiles using coupled cluster models Phenotypic characterization of human colorectal cancer stem cells Cell Adhesion Molecules and Ubiquitination-Functions and Significance Lesser-Known Molecules in Ovarian Carcinogenesis Stem cells, colorectal cancer and cancer stem cell markers correlations Cancer stem cells in colorectal cancer from pathogenesis to therapy: controversies and perspectives CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer Racial disparity in colorectal cancer: Gut microbiome and cancer stem cells Prognostic significance of the cancer stem cell markers CD133, CD44, and CD166 in colorectal cancer Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy A novel human recombinant single-chain antibody targeting CD166/ALCAM inhibits cancer cell invasion in vitro and in vivo tumour growth.Syntenin-1 and ezrin proteins link activated leukocyte cell adhesion molecule to the actin cytoskeleton Activated leukocyte cell adhesion molecule expression and shedding in thyroid tumors.Proteome of human colon cancer stem cells: a comparative analysis CDX2: Linking Cell and Patient Fates in Colon Cancer Prognostic impact of the expression of putative cancer stem cell markers CD133, CD166, CD44s, EpCAM, and ALDH1 in colorectal cancer.Characterization of the intestinal cancer stem cell marker CD166 in the human and mouse gastrointestinal tract Relevance of activated leukocyte cell adhesion molecule (ALCAM) in tumor tissue and sera of cervical cancer patients.Combination of osteopontin and activated leukocyte cell adhesion molecule as potent prognostic discriminators in HER2- and ER-negative breast cancer.Enhanced immunoPET of ALCAM-positive colorectal carcinoma using site-specific ⁶⁴Cu-DOTA conjugation.ALCAM (CD166) expression and serum levels in pancreatic cancer ALCAM regulates motility, invasiveness, and adherens junction formation in uveal melanoma cells.Identification of CD166 as a surface marker for enriching prostate stem/progenitor and cancer initiating cells Colorectal Cancer Stem Cells: Biology and Therapeutic Implications.Prognostic value of CD166 expression in cancers of the digestive system: a systematic review and meta-analysis.A seven-gene prognostic model for platinum-treated ovarian carcinomas.Combination of dasatinib and curcumin eliminates chemo-resistant colon cancer cells Clinical implication of CD166 expression in salivary gland tumor.An engineered cysteine-modified diabody for imaging activated leukocyte cell adhesion molecule (ALCAM)-positive tumors.ALCAM: Basis Sequence: Mouse Cytoplasmic overexpression of ALCAM is prognostic of disease progression in breast cancer A Pilot Study Assessing the Potential Role of non-CD133 Colorectal Cancer Stem Cells as Biomarkers.MCAM, as a novel receptor for S100A8/A9, mediates progression of malignant melanoma through prominent activation of NF-κB and ROS formation upon ligand binding.Activated Leukocyte Cell Adhesion Molecule (ALCAM) in Saudi Breast Cancer Patients as Prognostic and Predictive Indicator.Absence of DAB2IP promotes cancer stem cell like signatures and indicates poor survival outcome in colorectal cancer Verification of ALDH Activity as a Biomarker in Colon Cancer Stem Cells-Derived HT-29 Cell Line Bioimmunotherapy for melanoma using fully human antibodies targeting MCAM/MUC18 and IL-8.Intragenic G-quadruplex structure formed in the human CD133 and its biological and translational relevance

P2860

Q21296664-7A246D3B-9A0B-4E1D-9C2C-20258A55979D Q24542808-7F80942C-72B6-48AB-B6A5-0122758D63CA Q24564096-769CBC03-A996-423F-8162-AA0BC5CF9FB4 Q24674126-C40EDC8A-2E5B-4E0E-A138-A1775BB3E823 Q26771983-25B1DC66-D182-4328-AEAB-813403FCBF4F Q26784533-833349F8-68E8-494B-AF8E-E171014A2786 Q26823217-7306E295-F272-443A-A035-4BA226F4DE90 Q27024651-61C26E0D-2E89-4089-8BD7-BCB747D9DBC2 Q27853326-3A1093AA-C0F2-4037-8CE1-D6FA5BF6D92D Q28075465-00A96669-D92D-4163-B10F-199754D91352 Q28252750-985BB877-242D-4A62-8765-BB2237A6F4A4 Q33344524-217B4FB2-DCAA-4767-AE7B-BBB76DDCBF91 Q33634142-6E062006-B0CD-4056-B2AB-758FD033BB7F Q33676712-8C8C96EC-EB85-4216-87B1-72877362551D Q33833972-F4AB4E89-0F2D-4B27-A331-FAC001B6475D Q33859479-DBE22C38-DCE1-4A89-ABB2-3CA081A233E8 Q33872642-8D4418B1-CE28-406A-8DC3-8C57130689A5 Q34059673-5F06DE04-2A43-4C71-BD35-EDBBF47ED65C Q34136852-52ABEB1F-E353-4A7D-95C6-5B6E24C936B3 Q34220083-539E3699-06FB-4945-A095-5F7C5948D2DC Q34250074-E779DAB0-4044-43CE-A63F-B0FD2CFBD1AF Q34313174-B3F6D362-BEC7-4EF0-88D3-4C06ABB00AC2 Q34321201-B1357853-2066-42DF-9065-5B1E00F4F8E2 Q34321331-B560C07F-6F94-4366-A541-273EE950175E Q34374335-B9DBA7DE-D7A3-4843-BF0B-B13A574DBCE2 Q34921375-4D8D3531-B513-4ADB-9CB0-FAD50A57BA59 Q34936453-3CEDD276-9BAF-4127-94F8-84AC6800C1C6 Q35125629-24038A67-1927-4168-9261-C28BAAAD4778 Q35184278-62081A10-F23F-4A4C-BFD2-963F255784D9 Q35486869-54F6E035-2CF9-43FD-9CB5-D7236F317BDD Q35583305-DB6F403F-FE9E-4575-9055-3B58D1A7F74B Q35609716-C8D052D0-6542-4101-9A2A-C8CD36A3B38A Q35769956-EA719FEF-C297-4F6B-BBF6-444FFD40E731 Q36005675-98CDCBC2-55E2-4C64-950F-51AB85103FDA Q36010284-7A14D54B-1478-466F-9C0D-C7DCB16FE204 Q36089828-7FAD0D78-A586-4C52-ACA5-64516FDD5DF3 Q36275433-89437D9F-3D46-48F8-B65B-C8343178291B Q36340187-BDC5221F-8B46-426F-9ED1-B3BFBC64EAC9 Q36590676-D5EDBBFF-AE49-4996-B670-A275484AA4DE Q36627895-3709D492-3AFA-45FF-BCDC-2B0CB5213F12

P2860

ALCAM/CD166 is overexpressed in colorectal carcinoma and correlates with shortened patient survival.

http://www.wikidata.org/entity/Q41983868

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

2004年论文

@zh

2004年论文

@zh-cn

name

ALCAM/CD166 is overexpressed i ...... th shortened patient survival.

@en

type

label

ALCAM/CD166 is overexpressed i ...... th shortened patient survival.

@en

prefLabel

ALCAM/CD166 is overexpressed i ...... th shortened patient survival.

@en

P1433

Q41983868-2B48F044-4135-483F-BEB5-5443006EC20F

P1476

Q41983868-53A4EBE8-7FB4-45D0-A62C-9BFF971575D0

P2093

Q41983868-3A40D915-D9B5-4777-812E-D53B3848E3BB

Q41983868-5B218BFB-42CA-421B-851A-F9421E1764C6

Q41983868-9956FFE1-978C-466A-AD67-3BC7380CB7BC

Q41983868-AB889392-E943-4CBD-9F18-4178D0F952BD

Q41983868-F01D8436-E4CE-4190-89C6-50390BB60B3C

P2860

Q41983868-1F502ED6-F010-497E-BCD7-7A822761786F

Q41983868-51AC076A-E094-43F7-A959-F53F8C0DE371

Q41983868-541D4A6D-F058-4754-A0AE-1BF8A26C1EE2

Q41983868-5443B53B-0578-45BE-989C-C7C21CA4C972

Q41983868-56D74B4F-6E46-4BA7-A589-43332D639C75

Q41983868-5FD10823-E7C0-4EAC-960F-0209A88AB768

Q41983868-759616FE-E306-4F5A-BACE-C534C045C661

Q41983868-960952C2-5A22-44EA-8BEB-CF7DE02708B0

Q41983868-A7A3749B-1286-4160-A1E3-5AF84886ADB6

Q41983868-BCAF7797-FB26-4244-AAB5-B966AB941B3E

P304

Q41983868-C1A0F587-2F00-4176-9F2C-9E86ACD8DA1D

P31

Q41983868-0DAAAEE6-8460-446D-B9D7-6DC0FFBF64C9

P356

Q41983868-B5E72722-A4CC-40B2-8D31-713A4B50982B

P407

Q41983868-E89E2CAA-0269-4EA1-8C6E-6A41BD43CA48

P433

Q41983868-8240E21D-9D11-48C6-9C41-5EE4B2D60D28

P478

Q41983868-502B7CE4-9D4D-412B-B9F4-D5230E80282C

P577

Q41983868-E1473A5E-4916-4C34-ACC3-E967C88416DE

P5875

Q41983868-326DE3B3-DCD9-4659-A547-BEE6DB15C344

P698

Q41983868-F31F195C-6400-4C07-8952-EE5B6BE75079

P921

Q41983868-7B88F400-D3EC-4EE2-8874-22AFF6269A2E

Q41983868-B633D409-631B-4442-8153-734349137DB6

P932

Q41983868-0B56AB92-98FA-4D9E-8B14-B0A7586DFBDA

P356

JCP.2004.016238

P1433

Journal of Clinical Pathology

P1476

ALCAM/CD166 is overexpressed i ...... th shortened patient survival.

@en

P2093

Bellach J

http://www.w3.org/2001/XMLSchema#string

Dietel M

http://www.w3.org/2001/XMLSchema#string

Knösel T

http://www.w3.org/2001/XMLSchema#string

Kristiansen G

http://www.w3.org/2001/XMLSchema#string

Weichert W

http://www.w3.org/2001/XMLSchema#string

P2860

Cloning, mapping, and characterization of activated leukocyte-cell adhesion molecule (ALCAM), a CD6 ligand

MEMD, a new cell adhesion molecule in metastasizing human melanoma cell lines, is identical to ALCAM (activated leukocyte cell adhesion molecule)

Coordinate recruitment of E-cadherin and ALCAM to cell-cell contacts by alpha-catenin

ALCAM/CD166 is up-regulated in low-grade prostate cancer and progressively lost in high-grade lesions

Adhesion molecules, their receptors, and their regulation: analysis of CD6-activated leukocyte cell adhesion molecule (ALCAM/CD166) interactions.

Activated leukocyte cell adhesion molecule (CD166/ALCAM): developmental and mechanistic aspects of cell clustering and cell migration.

Identification and characterization of a 100-kD ligand for CD6 on human thymic epithelial cells.

Tumour markers of prognosis in colorectal cancer.

ALCAM (CD166): its role in hematopoietic and endothelial development.

Activated leukocyte cell adhesion molecule/CD166, a marker of tumor progression in primary malignant melanoma of the skin.

P304

1160-1164

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/JCP.2004.016238

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

57

http://www.w3.org/2001/XMLSchema#string

P577

2004-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8206945

http://www.w3.org/2001/XMLSchema#string

P698

15509676

http://www.w3.org/2001/XMLSchema#string

P921

P932

1770486

http://www.w3.org/2001/XMLSchema#string